More on Perrigo (PRGO -6%
: net profit +25% to $107.05M. Sales breakdown: Consumer Healthcare +12%, Nutritionals +10%, Rx Pharmaceuticals +70%. FY 2013 guidance
: adjusted EPS $5.30-$5.50 vs. $4.99 in the previous year and consensus of $5.42. Apart from the revenue miss, it's hard to see why the shares are getting battered.